TrialEuropean journal of nuclear medicine and molecular imaging2014

Individualized dosimetry-based activity reduction of ⁹⁰Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy.

Sofie Van Binnebeek et al.PubMed ↗Publisher ↗

No numbers read from the abstract.